Emcure Pharmaceuticals Stock Five Year Return
EMCURE Stock | 1,373 16.15 1.16% |
Emcure Pharmaceuticals fundamentals help investors to digest information that contributes to Emcure Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Emcure Stock. The fundamental analysis module provides a way to measure Emcure Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emcure Pharmaceuticals stock.
Emcure |
Emcure Pharmaceuticals Company Five Year Return Analysis
Emcure Pharmaceuticals' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
Competition |
According to the company disclosure, Emcure Pharmaceuticals has a Five Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers - Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all India stocks average (which is currently at 0.0).
Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
All Next | Launch Module |
Emcure Fundamentals
Profit Margin | 0.07 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 295.8 B | ||||
Shares Owned By Insiders | 86.77 % | ||||
Shares Owned By Institutions | 3.53 % | ||||
Price To Book | 9.39 X | ||||
Price To Sales | 3.92 X | ||||
Revenue | 69.17 B | ||||
EBITDA | 12.05 B | ||||
Book Value Per Share | 162.97 X | ||||
Earnings Per Share | 26.38 X | ||||
Target Price | 1575.0 | ||||
Market Capitalization | 270.98 B |
About Emcure Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emcure Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emcure Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emcure Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.